Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture

1. A glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene compound of general formula I

wherein

R 1 denotes hydrogen, fluorine, chlorine, bromine, iodine, C 1-4 -alkyl, C 2-6 -alkynyl, C 1-4 -alkoxy, C 2-4 -alkenyl-C 1-4 -alkoxy, C 2-4 -alkynyl-C 1-4 -alkoxy, methyl substituted by 1 to 3 fluorine atoms, ethyl substituted by 1 to 5 fluorine atoms, methoxy substituted by 1 to 3 fluorine atoms, ethoxy substituted by 1 to 5 fluorine atoms, C 1-4 -alkyl substituted by a hydroxy or C 1-3 -alkoxy group, C 2-4 -alkoxy substituted by a hydroxy or C 1-3 -alkoxy group, C 2-6 -alkenyl, C 3-7 -cycloalkyl, C 3-7 -cycloalkyl-C 1-3 -alkyl, C 3-7 -cycloalkyloxy, C 3-7 -cycloalkyl-C 1-3 -alkoxy, C 5-7 -cycloalkenyloxy, hydroxy, amino, nitro or cyano, while in the C 5-6 -cycloalkyl groups a methylene group may be replaced by O;

R 2 denotes hydrogen, fluorine, chlorine, bromine, hydroxy, C 1-4 -alkyl, C 1-4 -alkoxy, cyano or nitro, while the alkyl or alkoxy group may be mono- or polysubstituted by fluorine, and

R 3 denotes a 5- or 6-membered monocyclic heteroaryl-group which has 1 to 4 heteroatoms independently selected from the group consisting of N, O and S; or

a 8-, 9- or 10-membered bicyclic heteroaryl-group which has 1 to 4 heteroatoms independently selected from the group consisting of N, O and S; and wherein the ring of the bicyclic heteroaryl-group attached to the ether oxygen of the group —O—R 3 is heteroaromatic; and

wherein said heteroaryl-groups may possess 1 or 2 carbonyl groups as part of the mono- or bicyclic heteroaromatic ring-system; and

wherein an N-atom of said heteroaryl-groups may be oxidized to form the corresponding N-oxide; and

wherein one or more methine groups in said heteroaryl-groups may be substituted independently of one another with a substituent L1; and

wherein one or more imino-groups in said heteroaryl-groups may be substituted independently of one another with a substituent R N ; and

R 4 , R 5 independently of one another denote hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, C 1-3 -alkyl, C 1-3 -alkoxy or a methyl- or methoxy-group substituted by 1 to 3 fluorine atoms,

L1 independently of one another are selected from among fluorine, chlorine, bromine, iodine, hydroxy, cyano, C 1-3 -alkyl, difluoromethyl, trifluoromethyl, C 1-3 -alkoxy, difluoromethoxy, trifluoromethoxy, amino, C 1-3 -alkyl-amino and di(C 1-3 -alkyl)-amino; and

R N independently of one another are selected from among C 1-3 -alkyl; and

R 6 , R 7a , R 7b , R 7c independently of one another have a meaning selected from among hydrogen, (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, arylcarbonyl and aryl-(C 1-3 -alkyl)-carbonyl, while the aryl-groups may be mono- or disubstituted independently of one another by identical or different groups L1;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups which may be substituted as defined; and

while, unless otherwise stated, the above-mentioned alkyl groups may be straight-chain or branched,

the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof.

2. A glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene compound of general formula I.2

wherein the groups R 1 to R 6 and R 7a , R 7b and R 7c are defined as in claim 1 .

3. A glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene compound according to claim 1 , characterised in that the group R 3 is a 5- or 6-membered monocyclic heteroaryl-group wherein the term 5- or 6-membered monocyclic heteroaryl-group denotes a pyrrolyl, furanyl, thienyl, pyridyl or tetrazolyl group, or

a pyrrolyl, furanyl, thienyl or pyridyl group wherein one or two methine groups are replaced in each case by a nitrogen atom,

wherein the heteroaryl-group may possess 1 or 2 carbonyl groups as part of the heteroaromatic ring-system; and

wherein an N-atom of the heteroaryl group may be oxidized to form the corresponding N-oxide; and

wherein one or more methine-groups of the heteroaryl-group may be substituted independently of one another with a substituent L1; and

wherein one or more imino-groups of the heteroaryl-group may be substituted independently of one another with a substituent R N ;

wherein L1 and R N are defined as in claim 1 .

4. A glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene compound according to claim 1 , characterised in that the group R 1 denotes hydrogen, fluorine, chlorine, bromine, C 1-4 -alkyl, C 1-4 -alkoxy, methyl substituted by 1 to 3 fluorine atoms, methoxy substituted by 1 to 3 fluorine atoms, C 3-7 -cycloalkyloxy or C 3-7 -cycloalkyl-C 1-3 -alkoxy, while in the C 5-6 -cycloalkyl groups a methylene group may be replaced by O.

5. A glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene compound according to claim 1 , characterised in that the group R 2 denotes hydrogen, fluorine, chlorine, methyl, methoxy, ethoxy and methyl substituted by 1 to 3 fluorine atoms.

6. A glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene compound according to claim 1 , characterised in that the groups R 4 and/or R 5 independently of one another represent hydrogen or fluorine.

7. A glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene compound according to claim 1 , characterised in that the group R 6 denotes hydrogen, (C 1-8 -alkyl)oxycarbonyl, C 1-8 -alkylcarbonyl or benzoyl, preferably hydrogen.

8. A glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene compound according to claim 1 , characterised in that the groups R 7a , R 7b , R 7c represent hydrogen.

9. A physiologically acceptable salt of a compound according to claim 1 further comprised of inorganic or organic acids.

10. A pharmaceutical composition, containing a compound according to claim 1 optionally together with one or more inert carriers and/or diluents.

11. A method of treating metabolic disorders, said method comprised of the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the metabolic disorder is selected from the group consisting of type 1 and type 2 diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, edema and hyperuricaemia.

12. A method of inhibiting sodium-dependent cotrasporter SGLT2 said method comprised of the step of administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 1 or a pharmaceutically acceptable salt thereof.

13. A method for improving and/or restoring the functionality of pancreatic beta cells said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

14. A process for preparing a pharmaceutical composition according to claim 1 , wherein said compound is incorporated in one or more inert carriers and/or diluents by a non-chemical method.

15. A process for preparing the compounds of general formula I according to claim 1 wherein R 6 , R 7a , R 7b and R 7c represent hydrogen, characterised in that a compound of general formula III

wherein

R 8a , R 8b , R 8c , R 8d independently of one another have one of the meanings given for the groups R 5 , R 7a , R 7b , R 7c , but at least one of the groups R 8a , R 8b , R 8c , R 8d does not denote hydrogen, or denotes a benzyl group or a R a R b R c Si group or a ketal or acetal group, while in each case two adjacent groups R 8a , R 8b , R 8c , R 8d may form a cyclic ketal or acetal group or a 1,2-di(C 1-3 -alkoxy)-1,2-di (C 1-3 -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms a substituted dioxane ring together with two oxygen atoms and the associated two carbon atoms of the pyranose ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C 1-3 -alkoxy, and while benzyl groups may also be substituted by a di-(C 1-3 -alkyl)amino group; and

R a , R b , R c independently of one another represent C 1-4 -alkyl, aryl or aryl-C 1-3 -alkyl, while the alkyl or aryl groups may be mono- or polysubstituted by halogen;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R 1 to R 5 , R 6 , R 7a , R 7b , R 7c have the meanings given in claim 1 ,

is hydrolysed, and

optionally a compound of general formula I thus obtained wherein R 6 denotes a hydrogen atom is converted by acylation into a corresponding acyl compound of general formula I, and/or

if necessary any protective group used in the reactions described above is cleaved and/or

optionally a compound of general formula I thus obtained is resolved into its stereoisomers and/or

optionally a compound of general formula I thus obtained is converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.

16. A compound of general formula IV

wherein Hal denotes chlorine, bromine or iodine and the groups R 1 , R 2 , R 3 , R 4 and R 5 are defined as in claim 1 .

17. A compound of formula IV according to claim 16 , characterised by the formula

wherein Hal denotes chlorine, bromine or iodine and the groups R 1 , R 2 , R 4 and R 5 are defined as in claim 1 .

18. A compound of general formula II

wherein

R′ denotes H, C 1-4 -alkyl, (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, arylcarbonyl and aryl-(C 1-3 -alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;

R 8a , R 8b , R 8c , R 8d independently of one another have one of the meanings given for the groups R 6 , R 7a , R 7b , R 7c , or denote a benzyl group or a R a R b R c Si group or a ketal or acetal group, while in each case two adjacent groups R 8a , R 8b , R 8c , R 8d may form a cyclic ketal or acetal group or a 1,2-di(C 1-3 -alkoxy)-1,2-di (C 1-3 -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two associated carbon atoms of the pyranose ring, a substituted dioxane ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C 1-3 -alkoxy, and while benzyl groups may also be substituted by a di-(C 1-3 -alkyl)amino group; and

R a , R b , R c independently of one another denote C 1-4 -alkyl, aryl or aryl-C 1-3 -alkyl, while the alkyl or aryl groups may be mono- or polysubstituted by halogen;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R 1 to R 5 are defined as in claim 1 .